Acyclovir suppressive therapy

We use acyclovir 400 mg three times daily as suppressive therapy. Doses for suppressive therapy are higher in pregnant compared with nonpregnant

Suppressive therapy with acyclovir, famciclovir, or valacyclovir to a high-dose suppressive valacyclovir group (1,000 mg bid) in. ART

Over all, acyclovir is a safe and effective drug with acyclovir-resistant HSV in an infant on long term suppressive acyclovir therapy.

receiving suppressive daily dosage acyclovir and the patients receiving of daily suppressive acyclovir therapy remains unre¬ solved. Although this

The risks, benefits and alternatives to daily suppressive therapy should be Acyclovir suppression to prevent cesarean delivery after first-episode

According to the researchers, antisuppressive therapy for HSV2 can suppress clinical symptoms, but studies suggest that suppressive therapy with acyclovir and valacyclovir reduces the risk for

smear samples was determined in patients on suppressive therapy and in those naive to acyclovir therapy.We could not find any affect of long-term, low-dose acyclovir suppressive therapy on the susceptibility to acyclovir and on the frequen-cy of acyclovir-resistance of the virus population isolated directly from lesions of genital herpes.

Acyclovir, valacyclovir, and famciclovir are effective for suppressive and episodic therapy. Valacyclovir is the prodrug of acyclovir, and has

acyclovir-suppressive therapy. Thus, the low dose of acyclovir suppressive therapy did not affect the susceptibility to acyclovir or increase the fre-quency of acyclovir-resistant viruses in the geni-tal lesions. Keywords: genital herpes, herpes simplex virus, acyclovir, susceptibility Introduction 2024 International Medical Press